SRC and acute lymphoblastic leukemia: Dasatinib is a Bcr-Abl TKI and SRC family TKI [33, 35] that has been approved for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia [33, 35].